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ABSTRACT 
INTRODUCTION:  Chronic diarrhea caused by primary bile acid diarrhea (PBAD) is a common condition. 
We have previously shown PBAD is associated with low fasting serum levels of the ileal hormone, 
fibroblast growth factor 19 (FGF19).  FGF19 is a negative regulator of hepatic bile acid synthesis and is 
stimulated by farnesoid X receptor agonists, which produce symptomatic improvement in PBAD.  We 
aimed to assess possible causes for low serum FGF19 in patients with PBAD. 
METHODS:  Patients with PBAD, defined by reduced 75Se-labelled homocholic acid taurine (SeHCAT) 
retention, and idiopathic diarrhea controls had measurements of fasting lipids and fasting/post-prandial 
FGF19 serum profiles.  Specific functional variants in candidate genes were investigated in exploratory 
studies.  In further groups, basal and bile acid-stimulated transcript expression was determined in ileal 
biopsies and explant cultures by quantitative-PCR. 
RESULTS:  FGF19 profiles in PBAD patients included low fasting and meal-stimulated responses, which 
were both strongly correlated with SeHCAT.  A subgroup of 30% of PBAD patients had fasting 
hypertriglyceridemia and higher FGF19.  No clear significant differences were found for any genetic 
variant but there were borderline associations with FGFR4 and KLB.  SeHCAT retention significantly 
correlated with the basal ileal transcript expression of FGF19 (rs =0.59, p=0.03) and ASBT (rs=0.49, 
p=0.04), and also with the degree of stimulation by chenodeoxycholic acid at 6h for transcripts of FGF19 
(median 184-fold, rs=0.50, p=0.02) and IBABP (median 2.2-fold, rs=0.47, p=0.04).  Median stimulation of 
FGF19 was lower in patients with SeHCAT retention <10% (p=0.01). 
DISCUSSION:  These studies demonstrate a complex, multifactorial etiology of PBAD, including 
impairments in ileal FGF19 expression and responsiveness. 
Keywords: Bile acid malabsorption; functional gastro-intestinal disorders; IBS-D 
(257 words)  
  
Study Highlights  
1. WHAT IS CURRENT KNOWLEDGE  
 Chronic diarrhea due to bile acids is common but often unrecognized 
 Reduced median serum FGF19 has been shown in patients with primary bile acid diarrhea 
 The cause of reduced FGF19 is currently unknown 
2. WHAT IS NEW HERE  
 Hypertriglyceridemia is found in about 30% of patients with bile acid diarrhea who have normal 
FGF19 
 Patterns of serum FGF19 include low fasting and meal-stimulated levels 
 No major genetic differences in candidate genes have been identified 
 Ileal FGF19 transcript levels are significantly reduced in both basal conditions and after bile acid 
stimulation. 
 
  
INTRODUCTION 
Bile acid diarrhea (BAD) is a poorly recognized cause of chronic diarrhea and other symptoms 
such as urgency and fecal incontinence which may otherwise be diagnosed as the irritable bowel 
syndrome (IBS). (1-4)  Systematic reviews have suggested that up to 30% of diarrhea-predominant IBS 
patients, including those meeting Rome III IBS criteria, could have primary bile acid diarrhea (PBAD).  
These studies used data from abnormal 75SeHCAT tests, with patients having reduced 7d retention of 
this labelled bile acid and no obvious cause for bile acid malabsorption. (2,5-7)  SeHCAT values of 10-
15% are considered to be mild, 5-10% are moderate, and less than 5% are severe abnormalities.  Other 
diagnostic tests, including measurement of total fecal bile acids and fasting serum 7α-hydroxy-4-
cholesten-3-one (C4), a bile acid precursor, show increased fecal losses and synthesis of bile acids in 
PBAD. (3,4,8-10) 
Bile acid synthesis is regulated by the ileal hormone fibroblast growth factor 19 (FGF19) in 
humans, or by its orthologue FGF15 in rodents.  FGF15/19 synthesis is stimulated by absorption of bile 
acids in the ileum, which act through the principal nuclear bile acid receptor, farnesoid X receptor (FXR) 
to increase transcription by transactivation of specific target genes through response elements. (11,12)  
Low FGF15/19 results in increased bile acid synthesis; studies disrupting the FXR-FGF15/19 pathway in 
animal models have shown increased fecal bile acid loss and chronic diarrhea. The evidence for the role 
of this system has recently been reviewed. (10)  In humans, blood levels of FGF19 and C4 (as a measure 
of new bile acid synthesis) are inversely correlated and show considerable variation during the day 
following meals (13), in the healthy population overall, (14) and in patients with IBS. (3,15,16) 
Previous studies from our group demonstrated that patients with PBAD have low median fasting 
serum FGF19 concentrations. (17)  We suggested that this would result in overproduction of bile acids, 
which could exceed the capacity of the terminal ileum to reabsorb them, and would help explain earlier 
findings of a larger bile acid pool and no impairment of ileal uptake in PBAD. (18-20)  We have extended 
this finding in a larger prospective series of patients with chronic diarrhea, where PBAD patients have 
significantly lower, but variable, FGF19. (16)  Another group has confirmed low FGF19 in IBS patients 
with SeHCAT less than 10%. (3) 
The reasons for these varying reductions in FGF19 are currently unclear.  Consequently, the aim 
of these present studies was to determine whether specific potential mechanisms could be implicated.  
We performed a series of different investigations in our defined patient population, with bile acid 
retention defined by SeHCAT retention, to identify associated factors which could affect FGF19 
production and action.  First, as variable FGF19 patterns during the day following meals have been 
identified in preliminary studies in our earlier report, we wished to characterize these more thoroughly 
and define basal and meal-stimulated responses. (17)  Secondly, as hypertriglyceridemia has been 
previously linked to increased bile acid production and absorption, we aimed to determine the extent of 
this in our PBAD patients. (14,21,22)   
We also initiated exploratory studies of certain functional genetic variants, including those 
which have been identified in the FXR gene (NR1H4) (23,24) which might affect FGF19 production. We 
looked at variants in the FGF19 gene in the 3’-untranslated region which could affect transcript stability.  
Other candidate genes were explored where variation could affect intracellular bile acid concentration 
and FGF19 expression including the ileal bile acid transporters ASBT (SLC10A2) and OSTα (SLC51A). (25)  
Although they would not be expected to affect FGF19 serum levels, variations in the FGF19 receptor, 
FGFR4, and its co-receptor, Klotho-β (KLB), have been previously been identified in patients with IBS and 
are related to colonic transit. (4,26,27)  These could influence the overall responsiveness to FGF19 by 
affecting the specific signaling cascade of this hormone.  Furthermore, bile acids bind to the cell surface 
receptor known as TGR5 or GPBAR1 (gene GPBAR1), which is expressed on enteric neurons and 
endocrine cells.  TGR5 has been shown to be important for prokinetic actions of bile acids in mice colon, 
and variants have been associated with human colonic transit, fecal bile acids and IBS-D. (28) 
Additionally, variants of TNFSF15 have also been associated with IBS-D and could contribute to the 
disease mechanism. (29)  
Finally, we report separate experiments where we directly determined basal and bile acid-
stimulated transcript expression of FGF19 and other key genes in ileal explants obtained from patients 
with chronic diarrhea with known SeHCAT values.  In all these studies, we hypothesized that some of 
these mechanisms would be abnormal in subgroups of robustly phenotyped patients with PBAD. 
 
METHODS 
Patients  
Samples from 162 patients with chronic diarrhea were available for study of blood values and 
genetic variation.   90 of these have been included in a previous report of a prospective series from two 
sites. (16)  Additional patients were studied for ileal gene expression.  The composition of patient groups 
in the different studies is shown in Table1. 
All patients had a mean stool number of more than 3 per day, mean stool form on the Bristol 
stool form scale greater than 5, and a duration of more than 3 months.  Patients underwent standard 
testing including blood tests and colonoscopy or flexible sigmoidoscopy as clinically indicated to exclude 
other causes of diarrhea such as colorectal neoplasia, coeliac or inflammatory bowel disease.  SeHCAT 
tests were performed as recommended by the manufacturer (GE Healthcare, UK).  Patients with 7d 
SeHCAT  retention of <15% were diagnosed as having primary BAD; those with SeHCAT >15% were 
classed as idiopathic diarrhea controls (ID).  Subjects with various secondary causes of BAD, such as 
Crohn’s disease, ileal resection or cholecystectomy, were not included in these studies.  Participants 
gave fully informed consent to be included in research studies as approved by the institutional review 
board of the Research Ethics Committee of the Hammersmith and Queen Charlottes & Chelsea 
Hospitals.  Fasting blood samples were taken and processed for FGF19, cholesterol and triglycerides and 
stored for subsequent DNA preparation.  
Assays 
Serum FGF19 was quantified by a commercially available assay (FGF19 Quantikine ELISA, Cat. 
No. DF1900; R&D Systems, Minneapolis, MN, USA).  Total bile acids were measured by a 3α-
hydroxysteroid dehydrogenase assay, and cholesterol and triglycerides were quantified by standard 
colorimetric techniques in the routine Clinical Chemistry laboratory. 
Meal-stimulated FGF19 response  
A subgroup of 19 subjects with PBAD were studied to determine post-prandial changes in FGF19 
over a six-hour time course.  After an overnight fast, blood was sampled every 90 minutes for 6 hours 
from approximately 09:00 to 15:00.  Meals were provided after the first fasting sample at 09:00 
(breakfast) and 12:00 (lunch).  The composition of the meals was as follows: breakfast, total weight 
395g, total energy 2153KJ, protein: carbohydrate: fat energy ratio 9%:71%:20%; lunch, total weight 
690g, total energy 2860KJ, protein: carbohydrate: fat energy ratio 11%: 58%: 31%.  
Three phenotypes of FGF19 response were identified as an arbitrary classification based on our 
findings: (i) Low-low (L - L), all 5 serum FGF19 levels <300pg/ml; (ii) Low-high (L - H), sample 1 
<200pg/ml, sample 4 or 5 >400pg/ml; (iii) High-high (H - H) samples 1 and 3 or 5 >300pg/ml.  FGF19 area 
under the curve (AUC) values were calculated.   
Genetic polymorphisms 
In a separate part of the study, genomic DNA was extracted from 75 subjects by standard 
techniques with PBAD and 86 ID control subjects.  Ten different candidate SNPs were analyzed:  two 
from the gene encoding FGF19 (rs1789170, rs948992), two from FXR (rs61755050, rs56163822), and 
one each from FGFR4 (rs376618), Klotho-β (rs17618244), ASBT (rs188096), OSTα (rs939885), GPBAR1 
(rs11554825) and TNFSF15 (rs7848647).  Genotyping of the SNPs was performed using Taqman 5’ allelic 
discrimination assays (Applied Biosystems, Foster City, CA, USA).  In exploratory studies we looked at 
allele frequencies and other genetic models including dominant and recessive genotype differences. 
Ileal transcript expression 
At routine diagnostic ileo-colonoscopy in 31 patients being investigated for unexplained 
diarrhea, additional biopsies were taken from the ileal mucosa with informed consent.  Colonoscopy 
was performed after standard bowel preparation and fasting for at least 6h.  No colonoscopic or 
histological abnormalities were detected in these patients.  All had SeHCAT test results. 
In 15 patients, biopsies were immediately stored in RNAlater for subsequent RNA extraction.  
These provided basal transcript values.  In the other 16 patients, bile acid stimulated transcript 
expression was investigated in explant culture as previously described. (12)  Groups of 2-3 biopsies were 
incubated separately with either bile acid-free culture media (unstimulated control), or 50μmol/L of 
chenodeoxycholate (CDCA) or glyco-CDCA (GCDCA).  After 6h, biopsies were harvested directly into 
RNAlater.  RNA extraction and cDNA synthesis was performed following standard methods.  Expression 
of FGF19 and other transcripts (including ASBT, IBABP, OSTα, OSTβ, SHP and FXR) were quantified 
relative to GAPDH by qRT-PCR as previously described. (12)   
Statistics 
Data were usually analyzed by non-parametric tests including Mann-Whitney U-test to compare 
medians and Spearman Rank correlation (rs ) to look for associations.  The parametric Student’s t-test 
was used to compare normally distributed means.  In the genetic association studies and other group 
studies, proportions were compared with Fisher’s exact test with two-tailed p values calculated .  A p 
value of <0.05 was considered significant.  No corrections in p values were made for multiple 
comparisons in these relatively small exploratory studies of SNP polymorphism frequency. 
 
RESULTS 
An additional 33 patients with primary BAD (SeHCAT retention < 15%) and 39 ID controls 
(SeHCAT > 15%) were recruited and added to those previously reported from our institution. (16)  These 
had similar clinical findings to those reported before, with median daily stool frequency of 5/d, Bristol 
stool form types of 6.0-6.5, abdominal pain in 57-63%, bloating in 68-74%, fecal incontinence in 36-39% 
and presence of symptoms for about 2 years before SeHCAT testing, none of which differed significantly 
between the two groups.  The median BMI was higher (27.0 vs. 24.0kg/m2, p=0.009) in the PBAD 
patients.  Biochemical differences were again as found previously; in particular the median fasting FGF19 
in the overall PBAD group was significantly lower than that in the ID controls (148 vs. 235 pg/mL, 
p=0.0005) In the entire group, FGF19 was positively associated with SeHCAT values (rs=0.33, p=0.0001), 
with age (rs=0.23, p=0.002) and with fasting bile acids (rs=0.32, p<0.0001).  FGF19 and BMI was not 
significantly related (rs= −0.11, p=0.09)    SeHCAT and BMI were weakly inversely associated (rs= −0.19, 
p=0.01) but SeHCAT and bile acids were not (rs= −0.03, p=0.71). 
Associations of FGF19 with lipids 
The associations between FGF19 and fasting serum lipids were determined in the patients 
where these were available.  The strongest associations were found between FGF19 and total 
cholesterol (rs=0.33, p =0.009, n=62) and LDL cholesterol (rs=0.34, p=0.01).  There was a non-significant 
association between FGF19 and HDL cholesterol (rs=-0.14, p=0.27).  
Serum triglycerides findings were notable.  Higher FGF19 concentrations were associated with 
higher serum triglycerides (rs=0.20, p=0.04).  As FGF19 correlates overall with SeHCAT retention, it might 
have been expected that triglycerides would correlate positively with SeHCAT retention.  However, 
there was a significant negative association between triglycerides and SeHCAT retention (rs=-0.27, 
p=0.005, n=106, Figure 1).  Triglycerides were associated with BMI (rs=0.35, p=0.0001), and age (rs=0.29, 
p=0.001).  Subjects with elevated triglycerides had significantly lower SeHCAT retention (median 8.0% 
vs. 19.5%, p=0.01).  Using cutoffs of triglycerides <2.4mmol/L and SeHCAT <15% showed a significant 
segregation (p=0.017, Fisher’s exact test) with most of the subjects with raised triglycerides (13 out of 
18) having PBAD with SeHCAT <15%.  Furthermore, of the other 5 subjects with triglycerides ≥2.4 
mmol/L, 3 out of 5 had SeHCAT retention of under 20%. 
In the PBAD group with SeHCAT <15%, those with triglycerides ≥ 2.4 mmol/L had a median 
FGF19 level which was significantly higher than that in those with low triglycerides (Table 2, p=0.05) and 
which was similar to the medians found in the ID or healthy control groups.  These subjects with 
elevated triglycerides and low SeHCAT retention may represent a separate subset of about 30% of PBAD 
with a different underlying etiology. 
Meal-stimulated FGF19 responses  
We looked at patterns of fasting and meal-stimulated FGF19 to see if we could further define 
different phenotypes (Figure 2, a - c).  Based on these patients and previous limited data, we defined 
arbitrary values for low (L) and normal high (H) fasting and meal-stimulated values.  Although 19 
subjects underwent serial FGF19 sampling, two subjects did not match the criteria for the subtypes and 
are not shown.  Of the remaining 17, 8 (47%) were defined as having the L - L response, 5 as L - H and 4 
as H - H. 
The 8 L - L individuals had significantly lower SeHCAT retention than the L - H group (4.4% vs. 
8.1%, p<0.05) and the H - H group (7.4%, p=0.07).  In the L - L group, 6 had SeHCAT retention of 5% or 
less, with the other 2 having retention of 6.7% and 11.6%.  SeHCAT retention in the 5 individuals with 
the L-H pattern was not significantly different to the 4 subjects with the H - H pattern.  There were no 
significant differences in clinical and biochemical parameters between these different groups of 
patients. 
The FGF19 AUC was lower for those with SeHCAT<5% than those with higher values (median 
701 pg/mL·6h vs. 1655 pg/mL·6h, p=0.023).  SeHCAT retention correlated with the AUC (p<0.05, Figure 
2d).  AUC tended to be associated with fewer bowel motions in 24h (p=0.13).  A higher FGF19 taken at 
the 15:00 time point was negatively associated with fewer bowel movements per 24h (rs=-0.53 p=0.02). 
Serum FGF19 and total bile acids at all the time points were related (rs=0.46, p<0.0001).  No 
significant relationship was found between the percentage change in total bile acids and FGF19 at the 
same point but they strongly correlated with changes in FGF19 90 minutes later (rs=0.51, p<0.001).  This 
delay may reflect the time needed for ileal FGF19 production (12) and was similar for all three patterns 
of response. 
There were no significant differences between the L - L, L - H or H - H groups in median fasting 
triglycerides (2.07, 2.65, 0.77 mmol/L) and there was no correlation between fasting triglycerides and 
FGF19 AUC.  There was however a strong correlation between fasting triglycerides and the percentage 
increase in FGF19 after breakfast between 09:00 and 10:30 (rs=0.59, p=0.005).  FGF19 rises more with 
higher fasting triglyceride levels; consistent with the concept that in those subjects with PBAD 
associated with hypertriglyceridemia, the pathogenesis is not related to a failure of FGF19 production. 
Associations with genetic variants 
Exploratory studies were performed to look for major differences in allelic frequencies of 
specific variants in candidate genes (Table 2).  DNA samples from 161 subjects were available but not all 
genotypes were performed in the entire cohort.  
Overall there were no differences in allelic frequency that reached significance at the 
uncorrected p=0.05 level when a SeHCAT cutoff of 15% was used to separate PBAD  patients and 
idiopathic diarrhea controls.  At lower SeHCAT cutoffs, the FGFR4 SNP rs376618 had borderline 
significant differences, with the minor C allele being less common.  (See Supplemental material for a 
detailed description.)   
We also looked at other models for dominant or recessive genotype effects.  The FGFR4 variant 
rs376618 had borderline significant differences in genotype frequency in PBAD compared with ID 
subjects, with genotypes containing the minor C allele less frequent at SeHCAT values of <10% 
(uncorrected p=0.01) and <5% (p=0.05).  Overall, TT subjects had a significantly lower SeHCAT to those 
in the combined CT/CC group (11 vs. 19, p=0.04). However there was a higher proportion of the C allele 
in the L – L phenotype compared to the other phenotypes (p=0.05).   
The KLB rs17618244 variant had borderline significance, with the minor A allele less frequent in 
PBAD patients (p=0.10 to p=0.12 depending on SeHCAT cutoff values). At the 15% cutoff value, the 
GG/GA genotypes were more common in the PBAD group (p=0.07). 
Basal levels of transcript expression in ileal biopsies 
Expression of FGF19 and other relevant transcripts was studied in ileal biopsies obtained at 
routine diagnostic colonoscopy from patients with chronic diarrhea who also had SeHCAT tests (Figure 
3).  Basal expression was studied in 15 patients:  8 had PBAD with SeHCAT values <15% (3 to 13%) and 7 
were ID controls (values >15%).  Two patients (SeHCAT 5% and 13%) were excluded from further 
analysis as ASBT, SHP and FGF19 transcript values were below detection limits, suggesting a non-ileal 
source of these biopsies.  
SeHCAT values in the 13 patients were significantly associated with FGF19 (rs=0.59, p=0.03) and 
with ASBT (rs=0.49, p=0.04) but not with the other transcripts (Figure 3 A & B).  Expression of FGF19 and 
ASBT were strongly correlated (Figure 3C, rs=0.88, p=0.0002).  Additionally IBABP correlated with OSTα 
(rs=0.87, p<0.0001) and IBABP with ASBT (rs=0.63, p=0.01).  FXR and SHP expression were associated 
with several genes in related pathways (FGF19, ASBT, IBABP, OSTα and each other) but OSTβ did not 
correlate with any other transcript (Table 3).   
All associations were stronger in the ID controls.  In the PBAD group, the associations of FGF19 
and ASBT with SeHCAT were absent.  Although the correlation of FGF19 and ASBT remained strong, 
those between FXR and OSTα or IBABP were lost. 
Stimulation of FGF19 transcript expression in explants 
FGF19 expression was studied in 16 patients with diarrhea in ileal explants cultured for 6h with 
CDCA , GCDCA or under control conditions.  Both bile acids were used to compare any effects that could 
be related to ASBT uptake of GCDCA compared with more non-specific uptake of CDCA.  
FGF19 transcript expression was stimulated in all subjects, with a median of 184-fold induction 
with CDCA, similar to values found previously in non-diarrheal subjects. (12)  The lowest fold changes in 
FGF19 expression were observed in biopsies from patients with the lowest SeHCAT retention values.  
Positive correlations were found between SeHCAT retention and the magnitude of the fold change in 
FGF19 expression stimulated by CDCA (Figure 3D, rs=0.54, p=0.01, n=16) and by GCDCA (Figure 3E, 
rs=0.61, p=0.07, n=7).  IBABP, OSTα and SHP transcripts were also significantly stimulated to lesser 
degrees but ASBT was not affected  (Table 4).  Apart from FGF19, only the degree of stimulation of 
IBABP correlated with SeHCAT (p=0.04).   
The median stimulation of FGF19 by CDCA was significantly lower in patients with SeHCAT 
retention <10% (n=5) compared with those >10% (n=11) at 16 vs. 182-fold (p=0.01).  Stimulation of 
IBABP, OSTα and SHP were not significantly different. 
 
DISCUSSION 
In patients with PBAD, defined by low SeHCAT retention, we have investigated and shown a 
variety of mechanisms may be implicated in producing the lower median fasting FGF19 values that we 
have previously identified.  These contributory mechanisms include fasting hypertriglyceridemia and 
different basal and meal-related responses.  We have shown impaired ileal FGF19 transcript expression 
in the basal state and also impaired bile acid-dependent stimulation.  Exploratory studies of possible 
candidate genetic variation shows only weak associations, which will need confirmation in larger series, 
with greater power, but these current findings do indicate there is no large effect from any of the 
particular functional genetic variants we chose to study. 
Our studies indicate that different phenotypes can be defined in patients with PBAD.  This may 
explain the variability we encountered previously in fasting FGF19 serum values, which reduced the 
predictive value of a single test. (16)  The higher FGF19 values found in the patients with fasting 
hypertriglyceridemia suggest these patients constitute a different subgroup and are in keeping with 
previous work.  Gälman and colleagues studied a large group of over 400 normal subjects without 
clinical diarrhea, with measurements including FGF19, C4 and triglycerides. (14)  Overall they found a 
negative correlation between FGF19 and corrected C4, and between C4 and triglycerides.  In their 
patients with high C4 above the 95th percentile, 35% had raised triglycerides >2.4mmol/L.  This is a 
similar proportion to that found in our PBAD patients (30%), who would also be expected to have raised 
C4. (30)  Patients with familial hypertriglyceridemia have been shown to have an increased rate of bile 
acid synthesis and abnormal bile acid absorption has been suggested. (21)  These patients have been 
shown to have reduced expression of ASBT mRNA and protein to about half of control values (22), but 
no putative causative genetic variant that can explain this has been identified. (31)  We have not shown 
whether these patients with high triglycerides in our cohort with diarrhea have reduced ASBT.  It is 
unclear why they should have essentially normal fasting FGF19 values, but they do appear to constitute 
a subgroup of about 30% with a markedly altered lipid profile, meriting further study. 
We had found preliminary evidence for different fasting and meal-stimulated FGF19 responses 
in our initial study of PBAD patients (17) and now have defined these patterns more clearly.  Almost half 
the PBAD patients had the L – L pattern, where fasting and post-prandial samples were all below 
200pg/mL, which differs from the typical meal-stimulated response in healthy subjects shown 
previously. (13)  The lack of significant FGF19 response resembles a normal fasting pattern, but this L – L 
pattern is also similar to that which we have recently shown in ileal Crohn’s disease. (32)  These PBAD 
patients tend have a more severe phenotype, with a lower SeHCAT, but this pattern can also be found 
with lesser reductions in SeHCAT.  We only studied responses for 6h and a more prolonged study could 
yield further patterns.  Additionally, it is unclear why some patients have the initial high FGF19 of the H 
– H phenotype; this could be due to prolonged stimulation overnight, lack of fasting or perhaps a stress 
response related to the demands of the study and venesection. 
An impaired hepatic response to FGF19 due to functional genetic variation in components of the 
receptor pathway (FGFR4, KLB or further downstream) could also result in excessive bile acid synthesis 
and high FGF19 levels.  Variants in the FGFR4 and KLB genes described by Camilleri and colleagues are 
particularly interesting in this regard. (26,27)  They have been shown to be associated with colonic 
transit and to interact with each other.  Furthermore, interactions have previously been demonstrated 
for KLB variations with GPBAR1, which codes for the cell-surface bile acid receptor TGR5 and is likely 
involved with colonic transit. (33)   
We found no overall significant differences for any of the gene variants we studied in allele 
frequency between the PBAD and ID groups, defined with a SeHCAT cutoff of 15%. We acknowledge 
these groups are unpowered and type II errors may have occurred.  There were borderline significant 
differences in allelic frequency for FGFR4 at lower SeHCAT cutoffs and in genotype frequencies for the 
FGFR4 and KLB variants in the small subgroups, and different SeHCAT median values.  It must be borne 
in mind that we have not corrected for multiple comparisons and so the preliminary, exploratory nature 
of these results must be stressed.  This study does suggest however that these genes represent potential 
targets in appropriately powered much larger studies in patients with well-defined PBAD.  For instance, 
a study adequately powered (80% at α<0.05) to show the difference in proportions we found for the KLB 
variant would need 500 subjects in each group.  However, our findings are a reminder that these 
patients are predicted to have impaired activity in the bile acid-FXR-FGF19 hormonal pathway but will 
not have low blood FGF19 levels. 
The transcript data obtained with ileal biopsies and explant cultures were particularly 
informative.  FGF19 transcripts are significantly lower in basal, unstimulated, fasting samples from 
patients with lower SeHCAT values.  However ASBT transcripts are also lower; if ASBT protein levels are 
also reduced, it is likely that that this results in reduced bile acid uptake and consequently reduced bile 
acid/FXR-dependent stimulation of FGF19 transcription.  This association of ASBT and FGF19 is the 
strongest of those found in basal levels, which again have not been corrected for multiple comparisons, 
so the relevance of the weaker associations is less certain.  This data again will require further 
confirmation but this finding would be relevant to the reduced fasting FGF19 blood levels we have 
shown.   
Incubation with CDCA also gives FGF19 transcript stimulation which is related to SeHCAT values.  
Unconjugated CDCA, unlike glycine-conjugated GCDCA, is not dependent on transport by ASBT and will 
produce FXR-mediated transcription in cells not expressing ASBT. (34,35)  Conceivably, higher levels of 
OSTα or IBABP expression would reduce the concentration of intracellular bile acids and the FXR signal, 
but there is little evidence to support this. (36) The similar relationship of SeHCAT with the stimulation 
of IBABP, although this is much lower than FGF19 (as also shown before), (12) suggests the defect in 
PBAD extends to at least one other FXR-regulated transcripts.  Other reasons for reduced FXR activity 
and FGF19 induction in the ileum are not clear.  Inflammation in Crohn’s ileitis results in lower FGF19 
levels, (32) but the current patients all had normal histological biopsies.  Inflammatory cytokines inhibit 
FXR and FGF15 in mouse intestine (37) and could be implicated.  FXR activity is affected by many other 
pathways; for instance, intestinal peroxisome proliferator-activated receptor α-UDP-glucuronosyl-
transferase signaling has recently been proposed. (38)  Other transcription factors may regulate 
FGF15/19 transcription.  Vitamin D and A responsiveness has been shown in mice (39) but we found no 
evidence to support this as being relevant in PBAD patients. (40)  Further possible mechanisms include 
impaired FXR activity due to SIRT1 downregulation (41,42) and the effects of the protein Diet1 on FGF19 
production. (43) 
Impaired ileal FXR responsiveness is predicted to result in reduced FGF19 production with 
impaired feedback inhibition of hepatic bile acid synthesis.  This increased bile acid synthesis leads to 
excessive fecal bile acid loss (including loss of SeHCAT) and the production of diarrhea.  It is of interest to 
note however that patients with PBAD are able to respond to more potent FXR agonists such as 
obeticholic acid. (44)  In our recent clinical study, 10 PBAD patients who had low median FGF19 but a 
range of different response patterns all had some increase in FGF19 with treatment.  This resulted in a 
median FGF19 which was similar to healthy controls, and gave improvement in clinical findings.  It will 
be instructive to perform further large, placebo-controlled studies where the present findings are taken 
into account and patients are carefully phenotyped, and genetic variants defined, to see if the most 
responsive patients can be identified. 
In conclusion, it appears that several phenotypic patterns of PBAD can be identified.  These can 
result in different patterns of FGF19, which may not be reduced in some patients with 
hypertriglyceridemia or possibly with certain receptor genetic variants.  Patients with severe PBAD, with 
SeHCAT retention values less than 5%, are more likely to have lower meal-related serum FGF19 levels 
and lower ileal transcript production has been shown.  A fuller characterization of these subgroups and 
their individual pathophysiological causes is needed in larger studies to expand on our exploratory 
findings, but if confirmed, an understanding of the different phenotypes of PBAD will help optimize 
stratified, patient-centered therapy in this understudied condition.  
TABLES 
 
Table 1:  Details of various studies performed 
 
  Study Patient numbers 
 Total Primary bile 
acid diarrhea a 
Idiopathic diarrhea 
controls 
SeHCAT, FGF19 162 69 (36b+33c) 93 (54b+39c) 
Triglycerides  106 47 59 
Meal-stimulated response 17 17 -- 
Genetic polymorphisms 161 75 86 
Basal ileal gene expression 15 8 7 
Stimulated ileal gene expression 16 5 11 
 
a Primary bile acid diarrhea was usually defined as SeHCAT <15% 7 day retention.  Some studies 
also analyzed data at 5% and 10% cutoff values.  b Patients from the previous report  (16); c 
additional patients. 
  
Table 2: FGF19 and SeHCAT in patients with PBAD grouped according to triglycerides 
 
Triglycerides 
(mmol/L) 
n FGF19 
(pg/mL) 
P SeHCAT 
% 
P 
≥ 2.4 13 236 ± 49  7.0  
< 2.4 31 150 ± 18 0.05 6.7 NS 
 
44 patients had SeHCAT retention <15% with fasting triglyceride and FGF19 measurements. 
Values shown are mean ± SEM, and the groups were compared by two-tailed t-test. 
  
Table3:  Summary of exploratory genetic studies of variants in candidate genes in PBAD 
Gene 
product 
Gene SNP  Position Number of 
subjects 
MAF P  
     ID PBAD ID PBAD   
FGF19 FGF19 rs1789170 G>A 3’-UTR 84 72 0.357 0.396 0.48  
  rs948992 A>G 3’-UTR 86 71 0.366 0.331 0.55  
FXR NR1H4 rs61755050 T>C Met173Thr 60 51 0 0.020 0.21  
  rs56163822 G>T Translation start 80 67 0.044 0.030 0.76  
FGFR4 FGFR4 rs376618 T>C Leu136Pro 86 70 0.285 0.221 0.24  
KLB KLB rs17618244 G>A Arg728Gln 86 71 0.186 0.120 0.12  
ASBT SCL10A2 rs188096 C>A Ala171Ser 86 71 0.098 0.113 0.71  
OSTα SLC51A rs939885 G>A Val86Ile 55 57 0.482 0.493 0.90  
TGR5 GPBAR1 rs11554825 T>C 5’-UTR 47 34 0.404 0.426 0.87  
TNFSF15 TNFSF15 rs7848647 C>T 5’-flanking 87 71 0.282 0.338 0.33 
 
 
MAF, minor allele frequency; ID, idiopathic diarrhea controls; PBAD, primary bile acid diarrhea. The 
results shown here are for PBAD and ID patients defined as SeHCAT <15% and >15% respectively (see 
text). 
  
Table 4:  Relationships of basal levels of ileal transcript expression in patients with chronic 
diarrhea and known SeHCAT values 
 
All Subjects 
  
SeHCAT FGF19 ASBT IBABP OSTα OSTβ SHP 
FGF19 rs 0.59 
      
 
p 0.03 
      
ASBT rs 0.49 0.88 
     
 
p 0.04 <0.001 
     
IBABP rs 0.35 0.41 0.63 
    
 
p 0.12 0.11 0.01 
    
OSTα rs 0.24 0.32 0.37 0.87 
   
 
p 0.22 0.17 0.10 <0.001 
   
OSTβ rs -0.08 0.18 0.08 -0.11 -0.02 
  
 
p 0.40 0.30 0.40 0.36 0.47 
  
SHP rs -0.04 0.61 0.53 0.55 0.51 -0.05 
 
 
p 0.44 0.02 0.03 0.02 0.04 0.44 
 
FXR rs 0.31 0.67 0.79 0.61 0.43 -0.18 0.54 
 
p 0.15 0.01 <0.001 0.01 0.07 0.28 0.03 
 
Spearman rank correlation coefficients (rs) and p values are shown for the relationships between 
expression for all 13 subjects.  Significant p values (<0.05) uncorrected for multiple comparisons 
are shown in bold. 
  
Table 5:  Stimulation of ileal transcripts by chenodeoxycholic acid and relationship to SeHCAT 
 
Transcript 
Stimulation by 
CDCA 
p 
Correlation with 
SeHCAT 
p 
FGF19 184 0.0005 0.54 0.01 
IBABP 2.2 0.002 0.47 0.04 
OSTα 2.8 0.001 -0.10 NS 
SHP 2.6 0.002 -0.16 NS 
ASBT 1.0 NS -0.05 NS 
 
Median values for the degree of stimulation (fold-changes) with CDCA 50µmol/L for 6h are 
shown with p values (Wilcoxon test).  The relationships between stimulation and SeHCAT values 
are shown as Spearman rank correlation coefficients and p values.  n=12-16 patients.  NS, 
p>0.05. 
  
Table 6: Possible subgroups of bile acid diarrhea based on pathophysiological factors  
 
Bile acid diarrhea 
Raised fecal BA 
Reduced SeHCAT retention 
Overproduction 
Primary BA Diarrhea 
Impaired reabsorption 
Bile Acid Malabsorption 
↓ Feedback inhibition of BA synthesis 
(BA-FXR-FGF19-FGFR4/KLB pathway) 
Associated with 
hypertriglyceridemia 
Secondary to 
ileal disease / 
resection 
Secondary to 
other intestinal 
disorders 
Impaired ileal FGF19 
production 
Hepatic resistance to 
FGF19 actions 
   
↓ Blood FGF19  
↓ Baseline FGF19 
 (associated ↓ ASBT) 
± ↓Stimulated FGF19 
(? associated with 
FGFR4/KLB variants) 
   
 
 
 
  
FIGURES 
Figure 1  The relationship of fasting triglycerides to SeHCAT 7day retention percentage.  106 patients 
were studied.  The linear regression line and values for SeHCAT=15% and for triglycerides=2.4mmol/L 
are shown. 
  
 Figure 2  Patterns of serum FGF19 during a 6 hour time-course.  Fasting samples were taken at 09:00 (9) 
and then every 90min until 15:00 (15).  Three differing patterns of individual response are shown (see 
text for definitions): (a) L – L; (b) L – H; (c) H – H.  (d) The relationship of the 6h area under the curve 
(AUC) for FGF19 to the SeHCAT 7d retention is shown for all patients. 
  
Figure 3  Ileal transcript expression. (A) – (C) are basal RNA expression, (D) and (E) fold-change in 
stimulated RNA expression. (A) ASBT RNA and relationship to SeHCAT; (B) FGF19 RNA and SeHCAT; (C) 
FGF19 and ASBT; (D) fold-change in FGF19 expression with CDCA (50μmol/L) and SeHCAT, and (E) fold-
change in FGF19 with GCDCA (50μmol/L) and SeHCAT.  FGF19 and ASBT values were corrected for 
GAPDH expression.  Linear regression lines are shown.  In (A) and (B) lines show SeHCAT values of 15%.   
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Results: Further associations with genetic variants 
A fuller description of the allelic and genotypic variants that were studied and the associations 
that were found is detailed below. 
 
FGF19 
For the two SNPs in the 3’-UTR of the FGF19 gene, no significant differences between the 
patient groups for allelic frequency and no dominance effects were found.   
 
FXR 
The FXR variant rs61755050 produces a non-synonymous change (Met173Thr) and has 
previously been shown to affect FXR function. (1)  Two subjects out of 111 successful genotypes were 
heterozygotes; both had severe PBAD (SeHCAT 3% and 2%), low serum FGF19 (59 and 149 pg/mL) with 
total fasting bile acids of 0.9 and 5.9 mmol/L respectively.  This result was not significant due to small 
sample size; power calculations for a significance of 0.05 and a power of 0.80 suggest around 500 
subjects would be required.  The other FXR variant, rs56163822, which produces a change at the 
translation start site and has been associated with IBD and intrahepatic cholestasis of pregnancy, (1,2) 
has a low MAF and no significant difference was found with these small groups.  One individual was 
homozygous for the minor allele but had ID with a SeHCAT value of 21% and a fasting FGF19 237 pg/mL. 
 
FGFR4 
The FGFR4 variant rs376618 has been linked to faster colonic transit in TT homozygotes. (3)  We 
found no significant difference in MAF at a SeHCAT cut-off of 15%, but at lower cutoff values of 10% and 
5%, the minor C allele was less frequent in PBAD than in ID patients, with uncorrected p values of 0.0127 
and 0.0507 (Supplemental table 1). 
When genotypes were looked at, there was a lower proportion of CT heterozygotes in PBAD 
compared with in ID subjects (24% vs. 43%) and CC + CT (i.e. C dominant) genotypes were also 
significantly less frequent compared to the TT  genotype (p = 0.053).  Proportions were significant at 
SeHCAT cutoffs of 10% and 5%.  TT subjects have a significantly lower SeHCAT to those in the combined 
CT + CC group (11% vs. 19%, p = 0.04) but FGF19 levels were not significantly different (214 vs. 178 
pg/mL, p = 0.33).  
 
Supplemental Table 1:  Analysis of FGFR4 SNP rs rs376618 at different SeHCAT values 
SeHCAT cutoff value Minor allele frequency  Genotype dominance model 
 C T C 
 ID PBAD p p p 
15% 0.285 0.221 0.241 0.567 0.053 
10% 0.300 0.167 0.013 0.548 0.009 
5% 0.279 0.140 0.051 0.694 0.047 
 
Idiopathic diarrhea (ID) patients have SeHCAT values greater than the cutoff and PBAD patients less than 
the cutoff value. 
 
KLB 
The rs17618244 SNP in the KLB gene has previously been shown to be associated with colonic 
transit in IBS with the G allele also linked to faster gut transit time in response to oral 
chenodeoxycholate acid. (3,4)  The G allele was more frequent in the PBAD group than in the ID group 
with p values about 0.1 for different SeHCAT cutoffs (see Supplemental Table 2). 
The GG or GA genotypes were more common than the AA genotype but with only borderline 
significance at the SeHCAT cutoff of 15% (p = 0.07).  Of the 8 subjects with the genotype AA, 7 had ID 
(SeHCAT ranging from 19 – 51 %), and only 1 had PBAD (SeHCAT 7%). 
 
Supplemental Table 2:  Analysis of KLB SNP rs17618244 at different SeHCAT values 
SeHCAT cut-off value Minor allele frequency  Genotype dominance model 
 A G  A  
 ID PBAD p p p 
15% 0.188 0.120 0.118 0.072 0.365 
10% 0.183 0.106 0.098 0.270 0.181 
5% 0.173 0.077 0.096 0.353 0.224 
 
Idiopathic diarrhea (ID) patients have SeHCAT values greater than the cutoff and PBAD 
patients less than the cutoff value. 
 
ASBT 
The rs188096 SNP in the SCL10A2 gene, encoding Ala171Ser in ASBT, has been found to be 
present in a family with congenital PBAD (5) and has been previously studied in larger groups of 
patients. (6)  No significant difference was found here although the sample size is low.  Three individuals 
had the AA genotype, one with ID (SeHCAT 37%) and two with severe PBAD (SeHCAT <2%).  All 3 
individuals were clinically otherwise unremarkable.  The ID individual had an unremarkable FGF19 of 238 
pg/mL and the two PBAD individuals also had atypical high FGF19 (260 and 313 pg/mL).  
 
OSTα 
The rs939885 SNP in OSTα had similar allelic frequencies in the two groups.   
 
GPBAR1 
 The rs11554825 SNP in the 5’-UTR of the GPBAR1 gene has been associated with colonic 
transit and fecal bile acids in IBS patients (7) but we found no differences in allelic or genotype 
frequencies between our patient groups. 
 
TNFSF15 
Although TNFSF15 is not involved with bile acids, SNPs including rs7848647 have been 
associated with post-infectious IBS and could have been increased in our ID controls. (8)  No significant 
difference was found in our patient groups. 
 
Relationships with FGF19 phenotypic variation 
In the 17 subjects where FGF19 was profiled throughout the day, allelic frequencies were 
compared between the L - L phenotype and the combined group of the other phenotypes.  The FGFR4 
SNP rs376618 showed a significantly higher proportion of the C allele in the L - L phenotype compared 
with the others (0.375 vs. 0.091, p = 0.05).  The ASBT SNP rs188096 has a higher proportion of the A 
allele in the L-L phenotype (0.250 vs. 0.091, p = 0.22), and the FGF19 SNP rs948992 had a lower 
proportion of the G allele in the L - L group than the rest (0.188 vs 0.455, p = 0.17), but neither 
difference reached significance. 
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